The Combination of Remnant Cholesterol and Waist Circumference Offers Predictive Value for Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study from a Medical Examination Center

References

• Huang DQ, Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388–398. doi:10.1038/s41575-023-00759-2
   PubMed Web of Science ®Google Scholar
• Clayton-Chubb D, Kemp W, Majeed A, Lubel JS, Hodge A, Roberts SK. Understanding NAFLD: from case identification to interventions, outcomes, and future perspectives. Nutrients. 2023;15(3):687. doi:10.3390/nu15030687
   PubMed Web of Science ®Google Scholar
• Golabi P, Isakov V, Younossi ZM. Nonalcoholic fatty liver disease: disease burden and disease awareness. Clin Liver Dis. 2023;27(2):173–186. doi:10.1016/j.cld.2023.01.001
   PubMed Web of Science ®Google Scholar
• Jaiswal V, Ang SP, Huang H, et al. Association between nonalcoholic fatty liver disease and atrial fibrillation and other clinical outcomes: a meta- analysis. J Investig Med. 2023;71(6):591–602. doi:10.1177/10815589231164777
   PubMed Web of Science ®Google Scholar
• Björkström K, Widman L, Hagström H. Risk of hepatic and extrahepatic cancer inNAFLD: a population-based cohort study. Liver Int. 2022;42(4):820–828. doi:10.1111/liv.15195
   PubMed Web of Science ®Google Scholar
• Roderburg C, Krieg S, Krieg A, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD). Eur J Med Res. 2023;28(1):153. doi:10.1186/s40001-023-01114-6
   PubMed Web of Science ®Google Scholar
• Bardugo A, Bendor CD, Zucker I, et al. Adolescent nonalcoholic fatty liver disease and type 2 diabetes in young adulthood. J Clin Endocrinol Metab. 2021;106(1):e34–e44. doi:10.1210/clinem/dgaa753
   PubMed Web of Science ®Google Scholar
• Boccatonda A, Andreetto L, D’Ardes D, et al. From NAFLD to MAFLD: definition, pathophysiological basis and cardiovascular implications. Biomedicines. 2023;11(3):883. doi:10.3390/biomedicines11030883
   PubMed Web of Science ®Google Scholar
• Kong LX, Yang Y, Li HD, Shan YL, Wang X, Shan XF. Prevalence of nonalcoholic fatty liver disease and the related risk factors among healthy adults: a cross-sectional study in Chongqing, China. Front Public Health. 2023;11:1127489. doi:10.3389/fpubh.2023.1127489
   PubMed Web of Science ®Google Scholar
• Duan SJ, Ren ZY, Zheng T, et al. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease. World J Gastroenterol. 2022;28(36):5364–5379. doi:10.3748/wjg.v28.i36.5364
   PubMed Web of Science ®Google Scholar
• Ganda OP. Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease. Curr Opin Lipidol. 2023;34(3):105–113. doi:10.1097/MOL.0000000000000875
   PubMed Web of Science ®Google Scholar
• Baratta F, Cocomello N, Coronati M, et al. Cholesterol remnants, triglyceride-rich lipoproteins and cardiovascular risk. Int J Mol Sci. 2023;24(5):4268. doi:10.3390/ijms24054268
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Graif M, Yanuka M, Baraz M, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol. 2000;35(5):319–324. doi:10.1097/00004424-200005000-00006
   PubMed Web of Science ®Google Scholar
• Li RF, Liu J, Han P, Shi RF, Zhao LL, Li J. Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index. J Gastroenterol Hepatol. 2023;38(8):1316–1324. doi:10.1111/jgh.16196
   PubMed Web of Science ®Google Scholar
• Cabrera D, Moncayo-Rizzo J, Cevallos K, Alvarado-Villa G. Waist circumference as a risk factor for non-alcoholic fatty liver disease in older adults in Guayaquil, Ecuador. Geriatrics. 2023;8(2):42. doi:10.3390/geriatrics8020042
   PubMed Web of Science ®Google Scholar
• Zou Y, Lan JY, Zhong YJ, Yang S, Zhang HM, Xie GB. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis. 2021;20(1):139. doi:10.1186/s12944-021-01573-y
   PubMed Web of Science ®Google Scholar
• Chin J, Mori TA, Adams LA, et al. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents. JHEP Rep. 2020;2(6):100150. doi:10.1016/j.jhepr.2020.100150
   PubMedGoogle Scholar
• Ohnishi H, Saitoh S, Takagi S, et al. Relationship between insulin-resistance and remnant-like particle cholesterol. Atherosclerosis. 2002;164(1):167–170. doi:10.1016/s0021-9150(02)00057-6
   PubMed Web of Science ®Google Scholar
• Huang X, Ji Q, She CY, Cheng Y, Zhou JR, Wu QM. Ophiopogonin D ameliorates non-alcoholic fatty liver disease in high-fat diet-induced obese mice by improving lipid metabolism, oxidative stress and inflammatory response. Exp Ther Med. 2023;26(3):418. doi:10.3892/etm.2023.12116
   PubMed Web of Science ®Google Scholar
• Lee J, Kim H, Kang YW, et al. LY6D is crucial for lipid accumulation and inflammation in nonalcoholic fatty liver disease. Exp Mol Med. 2023;55(7):1479–1491. doi:10.1038/s12276-023-01033-w
   PubMed Web of Science ®Google Scholar
• Hegazy M, Saleh SA, Ezzat A, Behiry ME. Novel application of the traditional lipid ratios as strong risk predictors of NASH. Diabetes Metab Syndr Obes. 2020;13:297–305. doi:10.2147/DMSO.S229590
   PubMed Web of Science ®Google Scholar
• Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):371–379. doi:10.1016/j.jhep.2009.03.019
   PubMed Web of Science ®Google Scholar
• Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356–1362. doi:10.1002/hep.510300604
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar